Multidisciplinary fatigue management in patients treated with lenvatinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Multidisciplinary fatigue management in patients treated with lenvatinib

Published:2021-10-01 Issue:10 Volume:62 Page:601-612
ISSN:0451-4203
Container-title:Kanzo
language:en
Short-container-title:Acta hepatologica Japonica

Author:

Zenda Sadamoto¹,Ikeda Masafumi²,Kawaguchi Takumi³,Shomura Masako⁴,Miyazawa Yasushi⁵,Tauchi Junko⁶,Koya Shunji⁷,Endo Kaoru⁸

Affiliation:

1. Department of Radiation Oncology, National Cancer Center Hospital East

2. Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East

3. Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine

4. Faculty of Nursing, Tokai University School of Medicine

5. Department of Clinical Nutrition, Tokyo Medical University Hospital

6. Department of Pharmacy, National Cancer Center Hospital East

7. Division of Rehabilitation, Kurume University Hospital

8. Nutrition Division, Japanese Red Cross Musashino Hospital

Publisher

Japan Society of Hepatology

Subject

Hepatology

Link

https://www.jstage.jst.go.jp/article/kanzo/62/10/62_601/_pdf

Reference67 articles.

1. 1) Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (E7080): An angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014; 2014: 638747

2. 2) Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018; 391: 1163-1173

3. 3) Yamashita T, Kudo M, Ikeda K, et al. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol 2020; 55: 113-122

4. 4) Shimose S, Iwamoto H, Niizeki T, et al. Clinical significance of adverse events for patients with unresectable hepatocellular carcinoma treated with lenvatinib: A multicenter retrospective study. Cancers (Basel) 2020; 12: 1867

5. 5) Stone P, Richardson A, Ream E, et al. Cancer-related fatigue: Inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Annu Oncol 2000; 11: 971-975

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3